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ABSTRACT
Objective To quantify the unintended effects of statins
according to type, dose, and duration of use.
Design Prospective open cohort study using routinely
collected data.
Setting 368 general practices in England and Wales
supplying data to the QResearch database.
Participants 2004692 patients aged 30-84 years of
whom 225922 (10.7%) were new users of statins:
159790 (70.7%) were prescribed simvastatin, 50328
(22.3%) atorvastatin, 8103 (3.6%) pravastatin, 4497
(1.9%) rosuvastatin, and 3204 (1.4%) fluvastatin.
Methods Cox proportional hazards models were used to
estimate effects of statin type, dose, and duration of use.
The number needed to treat (NNT) or number needed to
harm(NNH)werecalculatedandnumbersofadditionalor
fewer cases estimated for 10000 treated patients.
Main outcome measure First recorded occurrence of
cardiovascular disease, moderate or serious myopathic
events,moderateor seriousliverdysfunction,acuterenal
failure, venous thromboembolism, Parkinson’s disease,
dementia, rheumatoid arthritis, cataract, osteoporotic
fracture, gastric cancer, oesophageal cancer, colon
cancer, lung cancer, melanoma, renal cancer, breast
cancer, or prostate cancer.
Results Individual statins were not significantly
associated with risk of Parkinson’s disease, rheumatoid
arthritis, venous thromboembolism, dementia,
osteoporotic fracture, gastric cancer, colon cancer, lung
cancer, melanoma, renal cancer, breast cancer, or
prostate cancer. Statin use was associated with
decreased risks of oesophageal cancer but increased
risks of moderate or seriousliver dysfunction, acuterenal
failure, moderate or serious myopathy, and cataract.
Adverse effects were similar across statin types for each
outcome except liver dysfunction where risks were
highest for fluvastatin. A dose-response effect was
apparent for acute renal failure and liver dysfunction. All
increased risks persisted during treatment and were
highest in the first year. After stopping treatment the risk
of cataract returned to normal within a year in men and
women. Risk of oesophageal cancer returned to normal
within a year in women and within 1-3 years in men. Risk
of acute renal failure returned to normal within 1-3 years
inmenandwomen,andliverdysfunctionwithin1-3years
inwomenandfromthreeyearsinmen.Basedonthe20%
threshold for cardiovascular risk, for women the NNT with
any statin to prevent one case of cardiovascular disease
over five years was 37 (95% confidence interval 27 to 64)
and for oesophageal cancer was 1266 (850 to 3460) and
formentherespectivevalueswere33(24to57)and1082
(711to2807).InwomentheNNHforanadditionalcaseof
acuterenalfailureoverfiveyearswas434(284to783),of
moderate or severe myopathy was 259 (186 to 375), of
moderate or severe liver dysfunction was 136 (109 to
175),andofcataractwas33(28to38).Overall,theNNHs
andNNTsformenweresimilartothoseforwomen,except
for myopathy where the NNH was 91 (74 to 112).
Conclusions Claims of unintended benefits of statins,
except for oesophageal cancer, remain unsubstantiated,
although potential adverse effects at population level
were confirmed and quantified. Further studies are
needed to develop utilities to individualise the risks so
that patients at highest risk of adverse events can be
monitored closely.
INTRODUCTION
Cardiovascular disease is the leading cause of prema-
turedeathandamajorcauseofdisabilityintheUnited
Kingdom.
1 Some meta-analyses and national policies
support the use of statins to reduce the risk of cardio-
vascular disease among high risk patients.
2-5 Validated
risk prediction algorithms, such as QRISK2, are used
toidentifyhighriskpatientsmostlikelytobenefitfrom
interventions,includingstatins.
67Giventhatstatinsare
already among the most widely prescribed medicines
and that their use is likely to continue to increase, both
their intended and their unintended effects and how
these vary by type, dose, and duration of use need to
be quantified in large representative populations. This
informationcanthenbeusedtoinformpolicyandclin-
icalpracticebysupplementinginformationfrommeta-
analyses of clinical trials, which tend to lack sufficient
detail, duration of follow-up, or sufficient power to
make some of the relevant comparisons.
23589 Also,
meta-analyses can be subject to selection bias as trial
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more healthy than real world populations, thus limit-
ing generalisability and external validity.
8
We carried out a large population based study to
examine a range of clinical outcomes that have been
found to be positively or negatively associated with
statin use, including moderate or serious myopathic
events,
10-13 Parkinson’s disease,
14 dementia,
1516 liver
dysfunction,
8917venousthromboembolism,
18rheuma-
toid arthritis,
19 cataract,
20 common cancers,
921-24 and
osteoporotic fracture.
25-27 We also included acute
renal failure as an outcome because of concerns pub-
lished both in The Lancet
28 and on the Food and Drug
Administrationwebsite,
29togetherwithreportsofpro-
teinuria in patients prescribed rosuvastatin.
30
METHODS
We carried out a prospective cohort study in a large
population of primary care patients using version 24
of the general practice research database, QResearch.
AllpracticesinEnglandandWalesthathadbeenusing
the computer based Egton Medical Information Sys-
tem (EMIS) for at least a year were included. Two
thirds of the practices were randomly allocated to the
study dataset and one third was retained for a subse-
quent study. We identified an open cohort of patients
aged 30-84 years from those registered with the prac-
tices between 1 January 2002 and 30 June 2008. We
excluded patients without a postcode related Town-
send score (about 4% of the population) and those
who had been prescribed statins before, or were cur-
rent users on, the date the study started. Entry to the
cohort was the latest of the date the study started,
12monthsafterthepatientregisteredwiththepractice,
or, for new users of statins, the date of their first pre-
scription. We censored patients at the earliest date of
the diagnosis of interest, death, deregistration with the
practice, last upload of computerised data, or the date
the study ended (31 December 2008).
Clinical outcomes
We examined several outcomes, identified from Read
codes recorded in the patients’ electronic records
(codes available from authors on request): acute renal
failure
2830; venous thromboembolism
18; Parkinson’s
disease
14; dementia
1516; rheumatoid arthritis
19;
cataract
20; osteoporotic fracture (spine, hip, or wrist);
common cancers (gastric, colon, oesophageal, lung,
renal,breast,prostate,melanoma);moderateorsevere
liver dysfunction, defined as an alanine transaminase
concentration>120IU/l(thatis,morethanthreetimes
the upper limit of normal) among patients without
diagnosed chronic liver disease, as this is the severity
at which guidelines recommend treatment is
discontinued
931; and moderate or serious myopathic
events,
9-1332 which for our study was defined as a diag-
nosis of myopathy or rhabdomyolysis or a raised crea-
tine kinase concentration of four or more times the
upper limit of normal, as this represents an event
where treatment is likely to be discontinued.
Table 1 |Baseline characteristics of study population of new users and non-users of statins.
Values are numbers (percentages) unless stated otherwise
Characteristics
New users
(n=225 922)
Non-users
(n=1 778 770)
Women 104 774 (46.4) 909 423 (51.1)
Men 121 148 (53.6) 869347 (48.9)
Ethnicity:
Recorded 121 355 (53.7) 569 466 (32.0)
White or not stated 215 077 (95.2) 1 699 991 (95.6)
Indian 2861 (1.3) 13 398 (0.8)
Pakistani 1658 (0.7) 7562 (0.4)
Bangladeshi 679 (0.3) 3226 (0.2)
Other Asian 759 (0.3) 7321 (0.4)
Caribbean 1788 (0.8) 9853 (0.6)
Black African 834 (0.4) 15 358 (0.9)
Chinese 316 (0.1) 4015 (0.2)
Other ethnic group 1950 (0.9) 18 046 (1.0)
Mean (SD) age (years) 57.2 (11.7) 44.4 (13.7)
Mean (SD) Townsend score −0.5 (3.3) −0.3 (3.4)
Mean (SD) systolic blood pressure (mm Hg) 141.1 (19.1) 129.9 (19.1)
Liver function test:
Recorded at baseline or before statins 131 354 (58.1) 162 207 (9.1)
Recorded at follow-up 193 586 (85.7) 594 750 (33.4)
Creatine kinase concentration:
Recorded at baseline or before statins 15 724 (7.0) 8642 (0.5)
Recorded at follow-up 62 706 (27.8) 43 333 (2.4)
Body mass index recorded 207 644 (91.9) 1 341 863 (75.4)
Mean (SD) body mass index 28.3 (4.9) 26 (4.6)
Smoking status recorded 224 982 (99.6) 1 615 527 (90.8)
Body mass index and smoking status recorded 207 494 (91.8) 1 330 320 (74.8)
Non-smoker 109 406 (48.4) 912 149 (51.3)
Former smoker 74 277 (32.9) 285 271 (16.0)
Current smoker:
Amount not recorded 2286 (1.01) 55 859 (3.1)
Light 14 447 (6.4) 116 035 (6.5)
Moderate 13 880 (6.1) 142 469 (8.0)
Heavy 10 686 (4.7) 103 744 (5.8)
Comorbidities:
Atrial fibrillation 11 656 (5.2) 13 730 (0.8)
Congestive cardiac failure 7457 (3.3) 9026 (0.5)
Cardiovascular disease 56 943 (25.2) 31 038 (1.7)
Peripheral vascular disease 8801 (3.9) 12 656 (0.7)
Treated hypertension* 97 782 (43.3) 106 582 (6.0)
Chronic kidney disease stage 3b+ 18 768 (8.3) 17 114 (1.0)
Type 1 diabetes 2843 (1.3) 2633 (0.2)
Type 2 diabetes 47 703 (21.1) 18 243 (1.0)
Endocrine disorders 2749 (1.2) 9347 (0.5)
Malabsorption 2156 (1.0) 11 079 (0.6)
Rheumatoid arthritis 3652 (1.6) 11 762 (0.7)
Systemic lupus erythematosus 264 (0.1) 1070 (0.1)
Asthma 23 307 (10.3) 1 394 85 (7.8)
Falls 10 333 (4.6) 21 805 (1.2)
Endocrine disorders 2749 (1.2) 9347 (0.5)
Any cancer 10 727 (4.8) 32 883 (1.9)
Hypothyroidism 12 378 (5.5) 30 357 (1.7)
Chronic liver disease 1016 (0.5) 3966 (0.2)
Colorectal polyps 1215 (0.5) 1989 (0.1)
Family history of breast cancer (women only) 3492 (1.6) 40 519 (2.3)
Benign breast disease (women only) 4343 (1.9) 32 187 (1.8)
Prescribed drugs:
Corticosteroids 13 868 (6.1) 44 517 (2.5)
Selective serotonin reuptake inhibitors 16 614 (7.4) 97 712 (5.5)
Tricyclic antidepressants 18 469 (8.2) 69 674 (3.9)
Depression 13 487 (6.0) 71 557 (4.0)
Hormone replacement therapy 5343 (2.4) 63 972 (3.6)
Oral contraceptives 303 (0.1) 72 334 (4.1)
Non-steroidal anti-inflammatory drugs (including aspirin) 125 127 (55.4) 362 589 (20.4)
Antipsychotic drugs 10 955 (4.9) 42 683 (2.4)
*Composite variable that includes recorded diagnosis of hypertension and treatment, which could include
angiotensin converting enzyme inhibitors, angiotensin receptor blockers, aldosterone, β blockers, thiazides, or
calcium channel blockers.
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Weidentifiednewusersofstatinsduringthestudyper-
iod,withtheremainingpatientsclassifiedasnon-users.
To correspond to an intention to treat analysis we
classified statin use by type of statin first prescribed
(atorvastatin, simvastatin, fluvastatin, pravastatin, or
rosuvastatin). We examined starting dose using cate-
gories similar to those published elsewhere,
3334 collap-
sing categories when data were insufficient to support
analysis.Wecompiledalistofpotentialpredictorvari-
ables, which included established risk factors for each
outcome from the literature or existing risk prediction
scores, using similar definitions when possible.
Statistical modelling
Toestimatethehazardratiosforeachoutcomefortype
of statin first prescribed for men and women sepa-
rately, we used Cox proportional hazards models to
comparenewuserswithnon-users,adjustingforpoten-
tial confounding variables. So that we considered first
events only we excluded patients from the analysis of
each outcome when they had a diagnosis of the out-
come at or before the baseline date. We used multiple
imputation to replace missing values for body mass
index and smoking status and used these values in
ourmainanalyses.
35-38Wecarriedoutfiveimputations.
When appropriate we used fractional polynomials to
model non-linear risk relations with continuous
variables.
39 When we found significant associations
for individual statins we examined the effects of dose.
We tested for interactions between statin use and age
and between smoking and deprivation and included
significant interactions in the final models. We carried
out two global tests; one to check that there was no
overall effect of individual statins, and, if that test
gave significant results a test for equality of effects of
individual statins. When the hazard ratio was less than
0.80 or greater than 1.20 and was statistically signifi-
cant at the 0.01 level we considered the effect of statins
to be significant.
Time varying analyses
When associations for individual statins were signifi-
cant, we used a time varying Cox regression analysis
toexaminetheeffectsofdurationofuseandtimesince
stopping any statin. We examined statins overall and
by type. To determine the risk of each outcome within
a year, 1-3 years, 3-5 years, and five or more years of
taking statins we compared non-users with new users.
We also determined change in risks after stopping sta-
tins, categorised as stopping treatment within a year,
1-3 years, and three or more years. The date of stop-
pingstatinswastakentobe90daysafterthedateofthe
last recorded prescription.
Self controlled case series analysis
Inaddition,weundertookposthocselfcontrolledcase
series analyses for the significant outcomes other than
cancer. The case series methodology was originally
developed to assess adverse events to vaccination
40
but has a wider application.
41-43 It can be used to deter-
mine the relative incidence of the outcome of interest
for periods of drug use compared with periods of non-
use inpeople withthe outcomeof interest.Inferenceis
within individuals and hence implicitly controls for
covariates that do not change over the study period.
Foreachoutcomeweselectedthepatientswithinthe
study cohort with the outcome of interest during the
study period and ascertained dates when they started
and finished taking statins. To improve adjustment for
Table 2 |Crude incidence per 10 000 person years for study outcomes in both men and women
Outcomes
Women Men
Incident
cases
Person
years
Rate per 10 000 person
years (95% CI)
Incident
cases
Person
years
Rateper10000person
years (95% CI)
Cataract 22 010 4 638 731 47.45 (46.83 to 48.08) 14 531 4 434 520 32.77 (32.24 to 33.31)
Osteoporotic fracture 13 475 4 646 441 29.0 (28.52 to 29.49) 4802 4 444 729 10.80 (10.50 to 11.11)
Breast cancer 9823 4 700 328 20.90 (20.49 to 21.32) NA NA NA
Prostate cancer NA NA NA 7129 4 486 286 15.89 (15.53 to 16.26)
Moderate or serious liver
dysfunction
7218 4 752 020 15.19 (14.84 to 15.54) 7802 4 491 763 17.37 (16.99 to 17.76)
Venous thromboembolism 6628 4 708 712 14.08 (13.74 to 14.42) 5571 4 475 491 12.45 (12.13 to 12.78)
Dementia 5505 4 759 939 11.57 (11.26 to 11.87) 3279 4 512 950 7.27 (7.02 to 7.52)
Rheumatoid arthritis 3961 4 717 553 8.40 (8.14 to 8.66) 1769 4 498 971 3.93 (3.75 to 4.12)
Lung cancer 2401 4 776 939 5.03 (4.83 to 5.23) 3600 4 519 197 7.97 (7.71 to 8.23)
Parkinson’s disease 1534 4 768 474 3.22 (3.06 to 3.38) 2019 4 509 935 4.48 (4.29 to 4.68)
Colon cancer 1970 4 769 095 4.13 (3.95 to 4.32) 2182 4 512 911 4.84 (4.64 to 5.04)
Melanoma 1174 4 767 753 2.46 (2.33 to 2.61) 896 4 516 849 1.98 (1.86 to 2.12)
Acute renal failure 860 4 777 274 1.80 (1.68 to 1.92) 1109 4 519 879 2.45 (2.31 to 2.60)
Oesophageal cancer 584 4 778 945 1.22 (1.13 to 1.33) 1225 4 521 683 2.71 (2.56 to 2.87)
Moderate or serious
myopathy
518 4 777 929 1.08 (0.99 to 1.18) 888 4 520 960 1.96 (1.84 to 2.10)
Gastric cancer 380 4 779 154 0.80 (0.72 to 0.88) 713 4 522 171 1.58 (1.47 to 1.70)
Renal cancer 959 4 775 022 2.01 (1.89 to 2.14) 2037 4 512 131 4.51(4.32 to 4.71)
NA=not applicable.
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the study period. To estimate relative rate ratios we
used conditional Poisson regression and adjusted for
ageinfiveyearbands.Wethendeterminedtherelative
rateratiosforindividualstatinsduringtheperiodofuse
and the washout period (1-182 days after stopping sta-
tins) compared with the baseline periods of non-usage
during each person’s observation time. We removed
the time period in the 28 days before starting statins
and the day on which the first prescription was issued.
For these analyses we combined men and women. As
the occurrence of an event may alter the probability of
subsequentstatin use we carried out an additional case
seriesanalysisrestrictedto newstatin users and started
the observation period at first use.
44
Number needed to treat or number needed to harm
We calculated the number needed to treat (NNT) or
number needed to harm (NNH) over five years for
patients at high risk of cardiovascular disease based
on a QRISK2 score of 20% or more, since this group
is eligible for statin treatment. For each outcome we
used Kaplan-Meier estimates to calculate the disease-
free probability at five years for non-users of statins in
thoseaged35-74years.Forthesecalculationswe iden-
tified a cohort of patientswho entered the studyon the
latest of their registration date and 1 January 2002 and
who had not been prescribed statins, or had the out-
come of interest by that date. These patients were cen-
soredattheearliestdateofthediagnosisofinterest,first
statin prescription, death, deregistration with the prac-
tice,last uploadofcomputerised data,or date atend of
study. We calculated adjusted hazard ratios for each
outcome for all types of statin treatment combined,
adjusting for potential confounding variables. We
then used these adjusted hazard ratios and the dis-
ease-free probability to calculate the NNT or NNH
for each outcome according to a published formula.
45
To enable comparisons and supplement data pub-
lished elsewhere we also used these values to calculate
thenumberofadditionalcasesper10000patientstrea-
ted over five years.
For cardiovascular disease, we used information
from a recent meta-analysis of 10 primary prevention
trials totalling over 70000 patients with risk factors for
cardiovascular disease but without cardiovascular dis-
ease at baseline who were treated with statins or pla-
cebo and followed up for a median of 4.1 years.
2 The
meta-analysis reported that the effects of statins on
major coronary events and cerebrovascular events
were not significantly different according to age, sex,
ordiabetesstatus.
2Wecombinedthe publishedresults
for major coronary events and cerebrovascular events
using a random effects model to calculate a summary
relative risk for cardiovascular disease in statin users
compared with non-users. We only included trials
that reportedboth outcomes, assuming that individual
patientsdidnot havebothoutcomes.Theoverall odds
ratio for cardiovascular events associated with statin
use in this meta-analysis was 0.76 (95% confidence
interval 0.67 to 0.86), which is similar to that reported
Table 3 |Risk associated with statin type both in men and in
women for non-significant and marginal outcomes
Outcomes
Adjusted hazard ratio (95% CI)
Women Men
Rheumatoid arthritis:
No statin 1.00 1.00
Simvastatin 0.96 (0.84 to 1.09) 1.12 (0.96 to 1.32)
Atorvastatin 0.97 (0.81 to 1.17) 1.06 (0.84 to 1.34)
Fluvastatin 1.00 (0.52 to 1.93) 1.07 (0.48 to 2.39)
Pravastatin 0.78 (0.49 to 1.26) 1.13 (0.68 to 1.88)
Rosuvastatin 0.84 (0.44 to 1.61) 0.72 (0.27 to 1.92)
Parkinson’sd i s e a s e :
No statin 1.00 1.00
Simvastatin 0.84 (0.71 to 1.00) 0.85 (0.74 to 0.98)
Atorvastatin 0.79 (0.61 to 1.01) 0.89 (0.73 to 1.08)
Fluvastatin 1.59 (0.87 to 2.89) 0.47 (0.21 to 1.06)
Pravastatin 0.89 (0.52 to 1.51) 0.73 (0.47 to 1.15)
Rosuvastatin 1.05 (0.50 to 2.20) 0.73 (0.35 to 1.54)
Venous thromboembolism:
No statin 1.00 1.00
Simvastatin 0.91 (0.83 to 0.99) 0.88 (0.80 to 0.97)
Atorvastatin 0.86 (0.76 to 0.99) 0.86 (0.75 to 0.97)
Fluvastatin 0.68 (0.41 to 1.13) 1.04 (0.70 to 1.54)
Pravastatin 1.05 (0.80 to 1.38) 1.00 (0.76 to 1.31)
Rosuvastatin 0.61 (0.36 to 1.03) 0.53 (0.29 to 0.95)
Dementia:
No statin 1.00 1.00
Simvastatin 0.88 (0.81 to 0.96) 0.92 (0.83 to 1.02)
Atorvastatin 0.84 (0.74 to 0.96) 0.86 (0.74 to 1.00)
Fluvastatin 0.96 (0.65 to 1.42) 0.83 (0.53 to 1.30)
Pravastatin 0.90 (0.68 to 1.18) 1.23 (0.94 to 1.60)
Rosuvastatin 0.66 (0.40 to 1.08) 0.74 (0.42 to 1.31)
Osteoporotic fracture:
No statin 1.00 1.00
Simvastatin 0.98 (0.92 to 1.05) 0.97 (0.87 to 1.08)
Atorvastatin 0.95 (0.87 to 1.04) 1.07 (0.93 to 1.24)
Fluvastatin 0.78 (0.57 to 1.08) 0.74 (0.44 to 1.26)
Pravastatin 0.91 (0.75 to 1.11) 1.00 (0.73 to 1.36)
Rosuvastatin 0.89 (0.65 to 1.21) 0.68 (0.36 to 1.26)
Gastric cancer:
No statin 1.00 1.00
Simvastatin 0.79 (0.55 to 1.13) 0.83 (0.65 to 1.04)
Atorvastatin 0.92 (0.57 to 1.49) 0.75 (0.53 to 1.06)
Fluvastatin 1.31 (0.32 to 5.28) 0.90 (0.33 to 2.41)
Pravastatin 0.85 (0.27 to 2.66) 0.65 (0.29 to 1.46)
Rosuvastatin 1.25 (0.31 to 5.05) 1.40 (0.58 to 3.39)
Colon cancer:
No statin 1.00 1.00
Simvastatin 0.89 (0.76 to 1.05) 1.02 (0.90 to 1.17)
Atorvastatin 0.85 (0.68 to 1.06) 0.90 (0.74 to 1.09)
Fluvastatin 0.25 (0.06 to 1.00) 1.14 (0.66 to 1.97)
Pravastatin 0.79 (0.46 to 1.34) 0.49 (0.28 to 0.86)
Rosuvastatin 1.03 (0.51 to 2.08) 2.04 (1.29 to 3.21)
Renal cancer:
No statin 1.00 1.00
Simvastatin 1.07 (0.86 to 1.32) 1.10 (0.97 to 1.26)
Atorvastatin 1.15 (0.86 to 1.54) 1.10 (0.91 to 1.32)
Fluvastatin 1.15 (0.43 to 3.07) 0.54 (0.24 to 1.21)
Pravastatin 0.99 (0.49 to 1.99) 1.02 (0.68 to 1.53)
Rosuvastatin 1.39 (0.58 to 3.37) 0.78 (0.37 to 1.65)
Lung cancer:
No statin 1.00 1.00
Simvastatin 1.10 (0.96 to 1.25) 1.11 (1.01 to 1.23)
Atorvastatin 0.88 (0.72 to 1.09) 0.95 (0.82 to 1.10)
Fluvastatin 0.13 (0.02 to 0.95) 0.81 (0.48 to 1.38)
Pravastatin 0.99 (0.64 to 1.54) 1.07 (0.78 to 1.46)
Rosuvastatin 1.28 (0.71 to 2.32) 0.83 (0.47 to 1.46)
Melanoma:
No statin 1.00 1.00
Simvastatin 1.02 (0.79 to 1.32) 1.11 (0.88 to 1.40)
Atorvastatin 0.94 (0.64 to 1.37) 1.20 (0.87 to 1.66)
Fluvastatin Insufficient data 1.59 (0.66 to 3.85)
Pravastatin 0.18 (0.02 to 1.27) 1.74 (0.98 to 3.10)
Rosuvastatin 0.79 (0.20 to 3.18) 1.12 (0.36 to 3.49)
Breast cancer:
No statin 1.00 1.00
Simvastatin 1.09 (1.00 to 1.18) NA
Atorvastatin 1.01 (0.90 to 1.14) NA
Fluvastatin 0.74 (0.45 to 1.21) NA
Pravastatin 0.93 (0.70 to 1.23) NA
Rosuvastatin 0.75 (0.47 to 1.19) NA
Prostate cancer:
No statin 1.00 1.00
Simvastatin NA 1.05 (0.98 to 1.13)
Atorvastatin NA 0.99 (0.89 to 1.10)
Fluvastatin NA 1.05 (0.77 to 1.44)
Pravastatin NA 0.85 (0.67 to 1.08)
Rosuvastatin NA 0.97 (0.67 to 1.40)
See web extra for variables that were adjusted for in hazard ratios.
NA=not applicable.
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3 We then combined this value with the
cardiovascular disease-free probability at five years to
calculate the NNT for cardiovascular disease and the
number of cases of cardiovascular disease prevented
per 10000 patients treated.
RESULTS
Overall, 557 general practices in England and Wales
supplying data to the QResearch database met the
inclusion criteria, of which 368 were randomly
assigned to the study dataset. In total, 2121786
patients were aged 30-84 at study entry, of whom
1778770 (83.8%) had not been prescribed statins,
9513 (0.5%) were past users, 107581 (5.1%) were cur-
rent users, and 225922 (10.7%) were new users during
the study period. Of the new users, 159790 (70.7%)
had been prescribed simvastatin, 50328 (22.3%) ator-
vastatin,8103(3.6%)pravastatin,4497(1.9%)rosuvas-
tatin, and 3204 (1.4%) fluvastatin.
Compared with non-users of statins, new users
tended to be older and were more likely to be men
and to have comorbidities such as atrial fibrillation,
cardiovascular disease, peripheral vascular disease,
treatedhypertension,diabetes,andchronickidneydis-
ease (table 1). They were also more likely to have
results recorded on computer for liver function tests
and creatine kinase concentrations.
Table 2 shows the crude incidence of each outcome
inmenandwomenseparatelyper10000personyears.
Overall, there were 1969 incident cases of acute renal
failure, 12199 of venous thromboembolism, 5730 of
rheumatoid arthritis, 36541 of cataract, 3553 of Par-
kinson’s disease, 8784 of dementia, 18277 of osteo-
porotic fracture, 1093 of gastric cancer, 1809 of
oesophageal cancer, 4152 of colon cancer, 6001 of
lung cancer, 2070 of melanoma, 2996 of renal cancer,
9823 of breast cancer, 7129 of prostate cancer, 15020
of moderate or serious liver dysfunction, and 1406 of
moderate or serious myopathy. Sixty two patients had
both acute renal failure and moderate or serious myo-
pathy.
Non-significant and marginal clinical outcomes
The associations between statins and Parkinson’s dis-
ease, rheumatoid arthritis, venous thromboembolism,
dementia, osteoporotic fracture, gastric cancer, lung
cancer, melanoma, renal cancer, breast cancer, and
prostate cancer were not clinically significant and the
overall tests for statins were not statistically significant
(at P<0.01) (table 3).
Although the association between any statin and
colon cancer was not significant in women, a signifi-
cant effect was present in men (overall P=0.002). The
riskofcoloncancerwaslowestamongmenprescribed
pravastatin (adjusted hazard ratio 0.47, 95% confi-
denceinterval0.28to0.86),althoughtherewasnoevi-
dence of a dose-response relation, and increased
among men prescribed rosuvastatin (2.07, 1.29 to
3.21). Time varying analysis showed that the risk was
increased after three years of treatment (3.27, 1.69 to
6.32) but returned to normal within a year of stopping
treatment.
Significant clinical outcomes
Outcomes significantly associated with statin use were
myopathy, cataract, acute renal failure, oesophageal
cancer, and moderate or serious liver dysfunction
(table 4).
Moderate or serious liver dysfunction
Overall, statins were associated with an increased risk
of liver dysfunction in both men and women (table 4).
In women there was some indication of differences
between the effects of individual statins (overall test
P=0.058). The highest risk was associated with fluvas-
tatin(2.53,1.84to3.47),whichwassignificantlyhigher
than that with simvastatin (1.52, 1.38 to 1.66). In men,
differences between the effects of individual statins
were significant (overall test P=0.0045). The highest
risk was associated with fluvastatin (1.97 1.43 to 2.72)
and the lowest with pravastatin (1.21, 0.93 to 1.58).
A dose-response effect was evident in women, with
an increased risk associated with higher doses
Table 4 |Risk of significant outcomes associated with statin
type both in men and in women
Outcomes
Adjusted hazard ratio (95% CI)
Women Men
Moderate or serious
myopathy:
No statin 1.00 1.00
Simvastatin 3.03 (2.35 to 3.91) 6.14 (5.09 to 7.40)
Atorvastatin 2.90 (2.09 to 4.01) 6.68 (5.32 to 8.39)
Fluvastatin Insufficient data 4.79 (2.12 to 10.80)
Pravastatin 2.64 (1.29 to 5.39) 4.84 (2.86 to 8.17)
Rosuvastatin 5.41 (2.64 to 11.07) 4.21 (1.87 to 9.48)
Acute renal failure:
No statin 1.00 1.00
Simvastatin 1.50 (1.23 to 1.83) 1.61 (1.37 to 1.90)
Atorvastatin 1.57 (1.22 to 2.03) 1.63 (1.31 to 2.02)
Fluvastatin 2.19 (1.13 to 4.27) 1.16 (0.55 to 2.44)
Pravastatin 2.07 (1.28 to 3.34) 1.71 (1.12 to 2.61)
Rosuvastatin 1.03 (0.39 to 2.78) 1.74 (0.86 to 3.50)
Cataract:
No statin 1.00 1.00
Simvastatin 1.30 (1.25 to 1.36) 1.31 (1.25 to 1.38)
Atorvastatin 1.30 (1.22 to 1.37) 1.32 (1.24 to 1.41)
Fluvastatin 1.26 (1.05 to 1.52) 1.16 (0.95 to 1.42)
Pravastatin 1.40 (1.24 to 1.57) 1.31 (1.15 to 1.50)
Rosuvastatin 1.25 (1.04 to 1.51) 1.56 (1.28 to 1.90)
Moderate or serious
liver dysfunction:
No statin 1.00 1.00
Simvastatin 1.52 (1.38 to 1.66) 1.54 (1.41 to 1.68)
Atorvastatin 1.53 (1.35 to 1.73) 1.56 (1.39 to 1.74)
Fluvastatin 2.53 (1.84 to 3.47) 1.97 (1.43 to 2.72)
Pravastatin 1.50 (1.15 to 1.97) 1.21 (0.93 to 1.58)
Rosuvastatin 1.31 (0.87 to 1.98) 1.46 (1.01 to 2.11)
Oesophageal cancer:
No statin 1.00 1.00
Simvastatin 0.69 (0.50 to 0.94) 0.82 (0.68 to 0.99)
Atorvastatin 0.73 (0.47 to 1.13) 0.73 (0.55 to 0.96)
Fluvastatin Insufficient data 0.60 (0.22 to 1.60)
Pravastatin 0.72 (0.27 to 1.92) 0.56 (0.28 to 1.13)
Rosuvastatin 0.41 (0.06 to 2.93) 0.91 (0.38 to 2.20)
See web extra for variables that were adjusted for in hazard ratios.
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Outcomes
Women Men
Cases/total
Adjusted hazard ratio
(95% CI) Cases/total
Adjusted hazard ratio
(95% CI)
Moderate or serious myopathy:
No statin 325/908 822 1.00 483/868 819 1.00
Simvastatin 10/20 mg/day 81/46 056 2.91 (2.19 to 3.88) 162/48 892 6.12 (4.97 to 7.55)
Simvastatin 40/80 mg/day 43/27 775 3.30 (2.32 to 4.69) 97/36 978 6.11 (4.79 to 7.80)
Atorvastatin 10 mg/day 42/17 065 2.98 (2.09 to 4.26) 80/18 601 6.11 (4.70 to 7.93)
Atorvastatin 20/40/80 mg/day 11/6488 2.62 (1.42 to 4.84) 39/8138 8.18 (5.82 to 11.50)
Fluvastatin 20 mg/day 0/575 Insufficient data 5/592 11.86 (4.88 to 28.85)
Fluvastatin 40/80 mg/day 0/906 Insufficient data 1/1126 1.20 (0.17 to 8.53)
Pravastatin 10/20 mg/day 4/1779 2.60 (0.96 to 7.04) 5/1932 3.62 (1.49 to 8.78)
Pravastatin 40 mg/day 4/1913 2.68 (0.99 to 7.25) 10/2476 5.79 (3.07 to 10.91)
Rosuvastatin all 8/2151 5.41 (2.64 to 11.07) 6/2345 4.19 (1.86 to 9.45)
Acute renal failure:
No statin 579/908 720 1.00 711/868 548 1.00
Simvastatin 10/20 mg/day 106/46 009 1.38 (1.10 to 1.74) 142/48 824 1.39 (1.14 to 1.70)
Simvastatin 40/80 mg/day 63/27 746 1.75 (1.32 to 2.32) 109/36 921 2.02 (1.63 to 2.52)
Atorvastatin 10 mg/day 57/17 048 1.43 (1.07 to 1.92) 85/18 556 1.63 (1.28 to 2.07)
Atorvastatin 20/40/80 mg/day 24/6479 2.03 (1.34 to 3.09) 24/8130 1.62 (1.07 to 2.44)
Fluvastatin 20 mg/day 7/577 4.35 (2.05 to 9.23) 1/591 0.48 (0.07 to 3.42)
Fluvastatin 40/80 mg/day 2/905 0.80 (0.20 to 3.21) 6/1121 1.50 (0.67 to 3.37)
Pravastatin 10/20 mg/day 8/1777 1.94 (0.96 to 3.92) 6/1929 0.98 (0.44 to 2.20)
Pravastatin 40 mg/day 10/1907 2.18 (1.16 to 4.09) 17/2476 2.31 (1.42 to 3.75)
Rosuvastatin all 4/2150 1.03 (0.38 to 2.78) 8/2344 1.73 (0.86 to 3.50)
Cataract:
No statin 16 543/896 717 1.00 10 068/861 216 1.00
Simvastatin 10/20 mg/day 2350/42 755 1.30 (1.24 to 1.36) 1848/46 566 1.32 (1.24 to 1.39)
Simvastatin 40/80 mg/day 1090/25 877 1.31 (1.23 to 1.40) 973/35 346 1.30 (1.21 to 1.40)
Atorvastatin 10 mg/day 1180/15 861 1.31 (1.23 to 1.40) 921/17 753 1.29 (1.20 to 1.39)
Atorvastatin 20/40/80 mg/day 334/6113 1.24 (1.11 to 1.39) 293/7882 1.44 (1.28 to 1.63)
Fluvastatin 20 mg/day 47/553 1.27 (0.95 to 1.69) 37/566 1.37 (0.99 to 1.89)
Fluvastatin 40/80 mg/day 71/833 1.26 (1.00 to 1.60) 61/1070 1.06 (0.83 to 1.37)
Pravastatin 10/20 mg/day 124/1662 1.24 (1.04 to 1.48) 108/1846 1.39 (1.15 to 1.68)
Pravastatin 40 mg/day 158/1778 1.55 (1.32 to 1.82) 124/2357 1.25 (1.05 to 1.50)
Rosuvastatin all 113/2029 1.25 (1.04 to 1.51) 98/2238 1.56 (1.28 to 1.90)
Moderate or serious liver dysfunction:
No statin 6055/907 313 1.00 6359/866 763 1.00
Simvastatin 10/20 mg/day 470/45 573 1.47 (1.32 to 1.63) 521/48 271 1.39 (1.25 to 1.54)
Simvastatin 40/80 mg/day 247/27 476 1.62 (1.41 to 1.86) 393/36 464 1.79 (1.60 to 2.01)
Atorvastatin 10 mg/day 221/16 948 1.37 (1.19 to 1.58) 277/18 412 1.45 (1.27 to 1.65)
Atorvastatin 20/40/80 mg/day 106/6440 2.00 (1.64 to 2.44) 127/8049 1.86 (1.55 to 2.24)
Fluvastatin 20 mg/day 10/574 1.64 (0.88 to 3.06) 8/592 1.20 (0.60 to 2.40)
Fluvastatin 40/80 mg/day 30/897 3.08 (2.14 to 4.43) 31/1120 2.37 (1.66 to 3.38)
Pravastatin 10/20 mg/day 19/1765 1.06 (0.68 to 1.67) 27/1904 1.31 (0.90 to 1.92)
Pravastatin 40 mg/day 37/1897 1.91 (1.37 to 2.65) 30/2453 1.13 (0.78 to 1.62)
Rosuvastatin all 23/2132 1.31 (0.87 to 1.97) 29/2316 1.46 (1.01 to 2.11)
Oesophageal cancer:
No statin 506/908 816 1.00 1009/868 647 1.00
Simvastatin 10/20 mg/day 31/46 067 0.62 (0.43 to 0.91) 104/48 893 0.91 (0.73 to 1.12)
Simvastatin 40/80 mg/day 19/27 788 0.82 (0.51 to 1.31) 42/36 968 0.66 (0.48 to 0.91)
Atorvastatin 10 mg/day 16/17 078 0.67 (0.40 to 1.11) 38/18 608 0.68 (0.49 to 0.95)
Atorvastatin 20/40/80 mg/day 7/6489 0.94 (0.44 to 2.00) 15/8138 0.86 (0.51 to 1.44)
Fluvastatin 20 mg/day 0/577 Insufficient data 1/593 0.46 (0.06 to 3.26)
Fluvastatin 40/80 mg/day 0/905 Insufficient data 3/1127 0.66 (0.21 to 2.07)
Pravastatin 10/20 mg/day 0/1779 Insufficient data 3/1933 0.48 (0.16 to 1.50)
Pravastatin 40 mg/day 4/1913 1.37 (0.51 to 3.67) 5/2477 0.62 (0.26 to 1.50)
Rosuvastatin all 1/2152 0.41 (0.06 to 2.92) 5/2345 0.91 (0.38 to 2.20)
Hazard ratios are adjusted for same variables as table 4 (see web extra).
RESEARCH
page 6 of 12 BMJ | ONLINE FIRST | bmj.comcomparedwithlowerdoses(table 5).Forexample,the
adjusted hazard ratio for fluvastatin was 3.08 (2.14 to
4.43) at high dose (≥20 mg) compared with 1.64 (0.88
to 3.06) at low dose (≤20 mg). The corresponding
values for men were 2.37 (1.66 to 3.38) and 1.20 (0.60
to2.40).Thispatternwassimilarwiththe otherstatins.
The risk of liver dysfunction was highest within the
first year of treatment with any statin: the adjusted
hazard ratio for women was 2.38 (2.11 to 2.70) and
formenwas2.32(2.07to2.59).Thehazardratiointhe
1-3 years after starting treatment for women was 1.39
(1.23to1.57)andformenwas1.35(1.21to1.51).After
stopping statins the risks returned to normal between
one and three years in women and from three years in
men. Further details on the analyses of duration are
available from the authors.
Moderate or serious myopathy
All statins were associated with an increased risk of
myopathy (table 4) apart from fluvastatin in women,
where numbers were too small for analysis. The direct
comparison test showed no significant difference
between the effects of individual statins either in men
(P=0.57) or in women (P=0.61).
The adjusted hazard ratios in table 5 show some
evidenceofadose-responseinmenprescribedatorvas-
tatin and pravastatin: 6.11 (4.79 to 7.80) for low dose
(10 mg/day) atorvastatin compared with 8.18 (5.82 to
11.50) for high dose (≥20 mg/day) atorvastatin, and
3.62 (1.49 to 8.78) for low dose (≤20 mg/day) pravas-
tatin compared with 5.79 (3.07 to 10.91) for high dose
(40 mg/day) pravastatin. The confidence intervals
were, however, wide owing to small numbers in each
dose category.
The time varying analysis showed that the risk was
highest within the first year of starting treatment: the
adjustedhazard ratio in women was 4.30 (2.98 to 6.21)
and in men was 9.96 (7.66 to 12.96). The increase per-
sisted during treatment as well as on stopping treat-
ment. From three years after stopping statins, the
adjusted hazard ratio in women was 4.65 (2.32 to
9.28) and in men was 5.86 (2.84 to 12.06).
Cataract
Eachstatinwasassociatedwithanincreasedriskofcat-
aractinbothmenandwomen,apartfromfluvastatinin
men, owing to small numbers. The direct comparison
test showed no significant difference between the
effects of individual statins in men (P=0.32) or in
women (P=0.82).
There was no evidence of a dose-response relation
(table 5). The time varying analysis showed the risk
wassignificantlyincreasedwithinayearofstartingsta-
tins, persisted during treatment, and returned to nor-
mal within the first year after stopping treatment.
Oesophageal cancer
The risk of oesophageal cancer decreased in both men
and women prescribed simvastatin (0.69, 0.50 to 0.94
and 0.82, 0.68 to 0.99, respectively). The risk was also
significantly decreased in men prescribed atorvastatin
(0.73, 0.55 to 0.96). The hazard ratios for the other
Table 6 |Relative incidence rate ratios from case series analysis for men and women combined for significant outcomes
associated with statin type
Outcomes
Incidence rate ratio (95% CI)
Acute renal
failure Cataract
Moderate or serious
liver dysfunction
Moderate or serious
myopathy
Simvastatin:
Period of non-use 1.00 1.00 1.00 1.00
Period of use 1.57 (1.27 to 1.95) 1.18 (1.13 to 1.24) 1.49 (1.36 to 1.63) 20.66 (14.68 to 29.06)
Washout period* 2.21 (1.40 to 3.5) 0.94 (0.8 to 1.11) 1.10 (0.86 to 1.41) 3.81 (2.04 to 7.11)
Atorvastatin:
Period of non-use 1.00 1.00 1.00 1.00
Period of use 1.17 (0.83 to 1.67) 1.18 (1.09 to 1.29) 1.62 (1.38 to 1.91) 8.48 (5.14 to 13.99)
Washout period* 1.60 (0.74 to 3.49) 0.77 (0.56 to 1.06) 0.90 (0.58 to 1.41) 2.84 (1.22 to 6.59)
Fluvastatin:
Period of non-use 1.00 1.00 1.00 1.00
Period of use Insufficient data 1.50 (1.04 to 2.15) 2.38 (1.24 to 4.57) 9.20 (0.84 to 100.97)
Washout period* Insufficient data 1.06 (0.37 to 2.99) 0.73 (0.10 to 5.55) Insufficient data
Pravastatin:
Period of non-use 1.00 1.00 1.00 1.00
Period of use 1.72 (0.69 to 4.25) 1.13 (0.92 to 1.4) 1.47 (0.95 to 2.26) 28.71 (5.51 to 149.56)
Washout period* 2.68 (0.53 to 13.51) 1.23 (0.67 to 2.24) 0.81 (0.25 to 2.69) Insufficient data
Rosuvastatin:
Period of non-use 1.00 1.00 1.00 1.00
Period of use 5.11 (1.05 to 24.92) 1.33 (1.01 to 1.75) 1.95 (1.11 to 3.41) 4.77 (1.27 to 17.88)
Washout period* 5.66 (0.55 to 58.49) 1.26 (0.54 to 2.93) 0.62 (0.08 to 4.64) Insufficient data
*1-182 days after stopping.
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they did not reach statistical significance possibly
because of small numbers. The direct comparison test
showed no significant difference between the effects of
individual statins in either men (P=0.76) or women
(P=0.99).
There was some evidence of a dose-response asso-
ciated with simvastatin in men only: adjusted hazard
ratio 0.91 (0.73 to 1.12) for low dose simvastatin (10/
20mg)and0.66(0.48to0.91)forhighdose(40/80mg)
simvastatin (table 5).
Thetimevaryinganalysisshowedthatthereduction
inriskofoesophagealcancerwasapparentonetothree
years after starting statins and persisted during the first
five years of treatment. In women the risk returned to
normal within the first year after stopping treatment
andinmenonetothreeyearsafterstoppingtreatment.
Acute renal failure
The risk of acute renal failure was increased in both
men and women prescribed simvastatin, atorvastatin,
and pravastatin(table 4) andin womenprescribedflu-
vastatin. The magnitudes of the adjusted hazard ratios
were similar for each statin, ranging from 1.50 to 2.19,
anddirectcomparisonsshowednodifferenceinriskby
type of statin (P=0.91 in men, P=0.37 in women). Too
few patients were prescribed rosuvastatin to draw firm
conclusions.
Evidence suggested a dose-response effect (table 5).
For example, for women prescribed simvastatin 10/
20 mg the adjusted hazard ratio was 1.38 (1.10 to
1.74) and for simvastatin 40/80 mg was 1.75 (1.32 to
2.32). For men the corresponding values were 1.39
(1.14 to 1.70) and 2.02 (1.63 to 2.52).
The increased risk of acute renal failure was appar-
ent within the first year of starting treatment (adjusted
hazard ratios 1.54 (1.09 to 2.17) for women and 1.67
(1.26 to 2.21) for men), and persisted for the first five
yearsoftreatment.Theriskremainedincreasedduring
the first year of stopping treatment and then returned
to normal 1-3 years after stopping treatment: adjusted
hazard ratios 1.23 (0.69 to 2.20) for women and 1.57
(0.95 to 2.60) for men.
Case series analysis
As in the cohort analysis the case series analysis for
moderate or serious myopathy showed increased
risks during statin use comparedwith no use, although
the magnitude of incidence rate ratios was larger than
thatinthecohortanalysisbutalsohadwideconfidence
intervals (table 6). The incidence rate ratios tended to
besmallerbut stillsignificant when thecase seriesana-
lysis was restricted to new users and the observation
Table 7 |Numbers needed to harm (NNH) or numbers needed to treat (NNT) and numbers of extra or prevented cases for each outcome over five years in
patients aged 35-74 free of cardiovascular disease at baseline with QRISK2 score of ≥20% or ≥15%
Variables
Adjusted hazard
ratio† for statin
use (95% CI)
High risk patients (QRISK2 score ≥20%) Medium risk patients (QRISK2 score ≥15%)
5 year risk of
outcome in
patients
unexposed to
statins
NNH or NNT
(95% CI)
Estimated No of
extra (or
prevented) cases
per10000patients
treated (95% CI)
5 year risk of
outcome in
patients
unexposed to
statins
NNH or NNT
(95% CI)
Estimated No of extra
(or prevented) cases
per 10 000 patients
treated (95% CI)
Women
Potential benefits:
Cardiovascular
disease*
0.76(0.67to0.86) 0.1184 −37 (−64 to −27) −271(−374to−157) 0.0989 −44 (−76 to −32) −228 (−315 to −132)
Oesophageal
cancer
0.68(0.52to0.88) 0.0025 −1266 (−3460 to −850) −8( −12 to −3) 0.0021 −1483 (−4053 to −996) −7( −10 to −3)
Potential harms:
Acute renal failure 1.56(1.31to1.86) 0.0041 434 (284 to 783) 23 (13 to 35) 0.0030 593 (388 to 1070) 17 (9 to 26)
Cataract 1.3 (1.26 to 1.35) 0.1089 33 (28 to 38) 307 (260 to 355) 0.0882 40 (34 to 47) 252 (213 to 292)
Liver dysfunction 1.53(1.41to1.66) 0.0140 136 (109 to 175) 74 (57 to 91) 0.0123 154 (125 to 199) 65 (50 to 80)
Myopathy 2.97(2.36to3.74) 0.0020 259 (186 to 375) 39 (27 to 54) 0.0016 313 (225 to 453) 32 (22 to 44)
Men
Potential benefits:
Cardiovascular
disease*
0.76(0.67to0.86) 0.1326 −33 (−57 to −24) −301(−417to−174) 0.1156 −38 (−65 to −27) −265 (−366 to −153)
Oesophageal
cancer
0.78(0.66to0.91) 0.0042 −1082 (−2807 to −711) −9( −14 to −4) 0.0037 −1236 (−3207 to −812) −8( −12 to −3)
Potential harms:
Acute renal failure 1.61(1.39to1.87) 0.0047 346 (245 to 539) 29 (19 to 41) 0.0037 447 (316 to 696) 22 (14 to 32)
Cataract 1.32(1.26to1.37) 0.0630 52 (44 to 63) 191 (158 to 225) 0.0495 66 (56 to 80) 151 (125 to 178)
Liver dysfunction 1.53(1.42to1.66) 0.0133 142 (115 to 180) 71 (56 to 87) 0.0122 155 (126 to 197) 64 (51 to 79)
Myopathy 6.15 (5.19 to 7.3) 0.0021 91 (74 to 112) 110 (90 to 134) 0.0018 106 (87 to 130) 95 (77 to 116)
Negative numbers indicate numbers needed to treat or cases prevented. Positive numbers indicate numbers needed to harm or extra cases.
*Odds ratios based on meta-analysis by Brugts et al.
2
†Adjusted hazard ratios for all statins combined adjusted for same variables as in tables 4 and 5 (see web extra).
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for simvastatin was 8.59 (95% confidence interval 5.2
to 14.19) and for atorvastatin was 4.37 (2.27 to 8.44).
Therateratioforpravastatinwashigher(33.89,3.87to
297.14). Data for fluvastatin and rosuvastatin were
insufficient for this analysis.
The case series analysis confirmed the significantly
increased risk of cataract during the period of use of
each statin compared with the period of non-use,
except for pravastatin: adjusted incidence rate ratio
1.13 (95% confidence interval 0.92 to 1.40). The risk
of acute renal failure was increased during simvastatin
use (1.57, 1.27 to 1.95) and also rosuvastatin use (5.11,
1.05 to 24.92) compared with non-use. The increased
risk of moderate or serious liver dysfunction during
statinusecomparedwiththeperiodofnon-useshowed
asimilarpatternandmagnitudetothecohortanalyses.
Numbers needed to treat and numbers needed to harm
Table 7showstheNNTsandNNHsforeachoutcome
among patients aged 35-74 who were at high risk of
cardiovascular disease, as defined by two thresholds
(≥20% and ≥15%) for cardiovascular risk based on the
QRISK2 10 year cardiovascular risk score.
Using the 20% threshold in women, the NNT with
anystatintopreventonecaseofcardiovasculardisease
over five years was 37 (95% confidence interval 27 to
64)andforoesophagealcancerwas1266(850to3460).
For men, the corresponding values were 33 (24 to 57)
and 1082 (711 to 2807).
In women, the NNH for an additional case of acute
renal failure over five years was 434 (284 to 783), for
moderateorseveremyopathywas259(186to375),for
moderate or severe liver dysfunction was 136 (109 to
175), and for cataract was 33 (28 to 38).
Overall,usingthe20%threshold,theNNHorNNTs
for men were similar to those for women except for
myopathy where the NNH was 91 (74 to 112). This is
lower than in women, mainly due to the higher hazard
ratio in men.
Table 7 also shows the NNH or NNT for men and
women selected using the 15% threshold for QRISK2
score.Theeventratesforeachoutcomeinnon-usersof
statins tended to be lower than when using the 20%
threshold. The effect of this was to increase both the
NNT and the NNH for each outcome. Table 7 also
shows the estimated numbers of extra cases or cases
prevented per 10000 people treated with statins at
boththresholds.Forexample,usingthe20%threshold
there would be 271 fewer cases (95% confidence inter-
val 157 to 374) of cardiovascular disease for every
10000 women compared with 228 fewer cases (132
to 315) using the 15% threshold.
DISCUSSION
We examined and quantified the unintendedrisks and
benefitsofstatinsinalargerepresentativeprimarycare
population over a six year period. Our study has good
face validity because it was carried out in a setting
where most patients in the United Kingdom are
assessed, treated, and followed up. We were unable
toconfirmsomepotentialunintendedeffectsofstatins,
such as a protective effect on risk of Parkinson’s dis-
ease, venous thromboembolism,
18 rheumatoid
arthritis,
19 osteoporotic fracture,
2546 and dementia.
1516
This may be because compared with most previous
studiesourstudywaslarger,prospective,andincluded
more potential confounders.
Our findings largely confirm other studies that
reported no clear association between statins and risk
of cancers.
921234748 There were two potential excep-
tions:oesophagealcancer,wherewefoundadecreased
risk, and colon cancer where there was an apparent
decreased risk in men prescribed pravastatin and an
increased risk in men prescribed rosuvastatin. These
findings could represent a genuine association or
could bedueto chance, giventhe largenumberof out-
comes under consideration in this study. Previous stu-
dies have not distinguished between the type of statin
and specific cancer to this degree
92123 or undertaken
individual patient level analyses. Some of the older
meta-analyses did not include rosuvastatin, which has
been licensed relatively recently.Further studiesusing
independentdatasetsshouldbeundertakentoconfirm
orrefutethesefindings,particularlyastheuseofstatins
is likely to increase.
We were able to quantify adverse effects associated
with statins, including myopathy, liver dysfunction,
acute renal failure, and cataract. These seem to be
class effects, with a dose-response effect apparent for
acute renal failure and liver dysfunction consistent
withthatreportedelsewhere.
928Wefoundasuggestion
of a dose-response for myopathy among men pre-
scribed pravastatin and atorvastatin, although the con-
fidence intervals were wide owing to small numbers.
As in previous studies, we found that adverse effects
tended to be similar across the types of statins for
most outcomes except for liver dysfunction, where
the highest risks were associated with fluvastatin. All
risks persisted during treatment and were highest in
the first year of treatment. After stopping treatment
the risk of cataract returned to normal within a year
in men and women. Risk of oesophageal cancer
returned to normal within a year in women and within
1-3yearsinmen.Riskofacuterenalfailurereturnedto
normal within 1-3 years in men and women, and liver
dysfunction within 1-3 years in women and from three
years in men.
Comparison with other studies
Clinical trials and their associated meta-analyses pro-
videvaluableinformationontheeffectivenessandeffi-
cacy ofdrugs.Theyare,however,limited in providing
information on adverse events since such data are not
always recorded or reported in a consistent fashion.
Trials tend to be of short duration, under-powered for
the detection of adverse events, and susceptible to
selectionbias,withparticipantstendingtobepredomi-
nantly white, younger, and healthier than the general
population. Most statin trials and meta-analyses are
designed to investigate the effectiveness of statins
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2Fewarespecificallydesigned
to investigate adverse events.
5
One systematic overview of 35 randomised trials
quantified the musculoskeletal, renal, and hepatic
effects associated with statin use. This study of 74102
predominantlywhitepatients,withameanfollowupof
17 months, reported a small excess risk of increases in
transaminase concentrations but no increase in risk of
myalgias, increased creatine kinase concentrations, or
rhabdomyolysis from statin use compared with
placebo.
8 The researchers concluded that further
study is necessary to determine how their results com-
pare with what occurs in routine practice, particularly
among patients who are older, have more severe
comorbid conditions, or receive higher statin doses
than most patients in these clinical trials.
8
Cholesterol Treatment Trialist Collaborators simi-
larly reported another large meta-analysis of statin
trials and reported no increased risk of cancer and a
lowexcessriskofrhabdomyolysis,witha0.01%excess
risk over five years.
3 They did not include liver dys-
function among the adverse outcomes, and other stu-
dies where this outcome has been reported have
tended to be small.
49
One observational studyexamined the comparative
safety of individual statins for selected outcomes,
including myopathy, acute renal failure, and acute
liver injury. This study used the general practice
research database and involved 100000 statin users
followed for under three years.
50 Our study adds to
this trial by examining a larger population of statin
users as well as including non-users, additional out-
comes, and a longer duration of follow up. There are
two main differences between our study and the gen-
eral practice research database study. Firstly, we com-
pared new users of statins with non-users whereas the
general practice research database study was designed
to compare different types of statins directly and did
not include a non-user group. Secondly, we used
more inclusive outcome definitions and identified
many more cases. In the general practice research
database study, in order for patients to be included as
cases they needed both a computer recorded code of
the outcome (for example, acute renal failure) and a
computer code indicating admission to hospital, and
if only one criterion was met the patient was not iden-
tified as a case. In our study we assumed that most
patients with, for example, acute renal failure would
be admitted to hospital and that the general practi-
tioner would record the diagnostic code rather than
the hospital admission itself.
Methodological considerations
Observational studies, with their large representative
and ethnically diverse populations and their potential
for longer term follow-up, have limitations, notably
bias and unmeasured confounding. Recall bias is not
of concern here because information on statin use was
prospectively recorded on computer before the out-
comes.Misclassification bias of use—that is,statin pre-
scriptions—is possible because low dose simvastatin
became available over the counter in August 2004.
However, it is likely that most prescriptions are issued
inprimarycareandrecordedelectronically,especially
among elderly people and those with comorbidities,
whowill have free prescriptions.Any misclassification
of statin use (or outcome) if non-differential, would
tendtobiasthehazardratiostowards1thusunder-esti-
matingapotentialassociation.Misclassificationofout-
come is possible, although validation studies
undertakenonsimilargeneralpracticedatabasesrelat-
ing to similar outcomes where the general practitioner
has been contacted for further detail have shown good
results.
1950
Ascertainment bias could occur as people starting
statins tend to have more blood tests than those not
starting statins thereby increasing the likelihood of
detectionofabnormalliverfunctiontestsormyopathy
associated with a raised creatine kinase concentration.
None the less, our study confirms the results of other
studies that statins are associated with liver
dysfunction
817 and gives information on the likely
volumes of affected people who need careful follow
up.Thisnotonlyhasplanningimplicationsforgeneral
practitioner workload but may cause anxiety for
patients. Our analysis, however, suggests that the risk
of abnormal liver function tests is dose dependent and
that it can be reversed on stopping treatment, both of
which could help guide therapy and reassure people.
Ascertainment or recording bias might also partly
account for the increased risk of cataract because peo-
ple prescribed statins may consult their general practi-
tioner more often than the general population thereby
increasing the opportunity for people to report on
visual problems and be examined.
51
Indicationbiasisparticularlyimportantforintended
outcomes such as the reduction in risk of cardio-
vascular disease. Initially, we carried out an additional
preliminary analysis using the prior event rate ratios
approach
52 and obtained similar point estimates to
those from the published meta-analyses. However,
the prior event rate ratios approach is not valid for
WHAT IS ALREADY KNOWN ON THIS TOPIC
Meta-analyses suggest that statins reduce the risk of cardiovascular disease, particularly in
high risk patients
Although meta-analyses provide valuable information on effectiveness they tend to lack
representative samples, duration of follow-up, or power to assess unintended effects
Informationontheunintendedeffectsofstatinsinrepresentativeprimarycarepopulationsis
lacking although statins are prescribed in large volumes for long periods
WHAT THIS STUDY ADDS
Individual statins were not significantly associated with risk of Parkinson’sd i s e a s e ,
rheumatoid arthritis, venous thromboembolism, dementia, osteoporotic fracture, and
several common cancers
The risk of oesophageal cancer was reduced but for liver dysfunction, acute renal failure,
myopathy, and cataract it was increased
Adverseeffectsweresimilaracrossthestatintypesforeachoutcomeexceptliverdysfunction
where fluvastatin was associated with the highest risks
RESEARCH
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nosis of an outcomebefore startingstudy drugswas an
exclusion criterion.
52 We have therefore used odds
ratios
2 derived from meta-analyses to work out the
numbersneededtotreatatpopulationlevelforcardio-
vasculardisease,combinedwitheventratesfromQRe-
search.
Our case series analysis generally confirms the
results of our main cohort analyses. It removes the
effects of fixed cofounders and largely removes the
effect of indication bias, although it could still be sus-
ceptible to ascertainment bias.
Clinical implications
At national level, our study is likely to be useful for
policy and planning purposes because we have given
theexpectednumbersofadditionaladverseeventsper
10000 patients that would occur if all patients likely to
be at high risk of cardiovascular disease were pre-
scribed statins, assuming the associations we found
are causal. We undertook our analyses for NNHs and
NNTs at two thresholds of cardiovascular risk (≥15%
and ≥20%) and showed that the potential benefits and
harms both tend to increase as the threshold for inter-
vention increases.
Our study may also be useful for informing guide-
lines on the type and dose of statins. Although adverse
outcomes tended to be class effects overall with no sig-
nificantdifferencesbetweenthestatins,theriskofliver
dysfunction was highest with fluvastatin. The risk of
liver dysfunction, acute renal failure, and possibly
myopathy were dose related and, as liver dysfunction
iscommonandtheothertwooutcomespotentiallylife
threatening, the findings would tend to support a pol-
icyof usinglowerdosesof statinsin peopleat highrisk
of the adverse event.
While we have shown adverse associations between
statin use and four outcomes and one protective asso-
ciation, our study was not designed to show causality.
Although we have shown some evidence of dose-
response relations and reversibility (in that risk for
most outcomes decreases on stopping treatment), con-
sideration of potential biological mechanisms is out-
side the scope of this study.
Conclusions
In summary, we have reported a detailed epidemiolo-
gical analysis of the unintended effects of statins in a
large representative primary care population for a
rangeofoutcomesbytypeofstatin,dose,andduration
ofuse.Wehavegivenestimatesonthenumberofaddi-
tional events potentially caused or prevented per
10000 patients treated. The current paper quantifies
risks and benefits of statins at population level, but
the underlying algorithms also can be applied at the
individual level. In a companion paper,
53 therefore,
we validate the algorithms at individual level so that
they can be used to explain absolute and relative risks
andbenefitsforanindividualpatientaswellastoiden-
tify those at high risk of adverse events from statins for
more proactive monitoring.
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